Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.

PubWeight™: 1.44‹?› | Rank: Top 5%

🔗 View Article (PMID 26857392)

Published in J Natl Cancer Inst on February 08, 2016

Authors

Markus A Schirmer1, Claudia M Lüske1, Sebastian Roppel1, Alexander Schaudinn1, Christian Zimmer1, Ruben Pflüger1, Martin Haubrock1, Jacobe Rapp1, Cenap Güngör1, Maximilian Bockhorn1, Thilo Hackert1, Thomas Hank1, Oliver Strobel1, Jens Werner1, Jakob R Izbicki1, Steven A Johnsen1, Jochen Gaedcke1, Jürgen Brockmöller1, B Michael Ghadimi1

Author Affiliations

1: Institute of Clinical Pharmacology (MAS, CML, SR, AS, CZ, RP, JB), Institute of Bioinformatics (MH), Clinic of General and Visceral Surgery (CML, SR, JR, SAJ, JG, BMG), and Clinic of Radiotherapy and Radiation Oncology (MAS), University Medical Center Göttingen, Göttingen, Germany; Department of General, Visceral, and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany (CG, MB, JRI); Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany (THac, THan, OS, JW).

Articles cited by this

Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32

JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res (2007) 8.79

Pancreatic cancer. Lancet (2011) 8.54

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21

Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19

WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79

Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet (2000) 2.56

Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A (2007) 2.37

WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12

The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat (2010) 2.09

Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A (2004) 1.91

Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res (2008) 1.52

The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res (2004) 1.45

JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem (2003) 1.44

An opposing view on WWOX protein function as a tumor suppressor. Cancer Res (2003) 1.27

A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26

Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res (2005) 1.21

Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J Biol Chem (2014) 1.19

Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem Pharmacol (2003) 1.11

Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci (2008) 1.00

ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med (2015) 0.93

A clustered set of three Sp-family genes is ancestral in the Metazoa: evidence from sequence analysis, protein domain structure, developmental expression patterns and chromosomal location. BMC Evol Biol (2010) 0.92

Low SP1 expression differentially affects intestinal-type compared with diffuse-type gastric adenocarcinoma. PLoS One (2013) 0.83

The role of WWOX tumor suppressor gene in the regulation of EMT process via regulation of CDH1-ZEB1-VIM expression in endometrial cancer. Int J Oncol (2015) 0.83